Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Voyager Therapeutics revenue
Voyager Therapeutics's revenue is $80.0 million.
What is Voyager Therapeutics's revenue?
- Voyager Therapeutics's revenue growth from 2015 to 2024 is 361.53%.
- Voyager Therapeutics has 123 employees, and the revenue per employee ratio is $650,414.
- Voyager Therapeutics's peak quarterly revenue was $150.5M in 2023(q1).
- Voyager Therapeutics peak revenue was $250.0M in 2023.
- Voyager Therapeutics annual revenue for 2023 was 250.0M, 511.16% growth from 2022.
- Voyager Therapeutics annual revenue for 2024 was 80.0M, -68.0% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Voyager Therapeutics historical revenue
Voyager Therapeutics's peak revenue was $250.0M in 2023. The peak quarterly revenue was $150.5M in 2023(q1).
Voyager Therapeutics's revenue increased from $17.3m in 2015 to $80.0M currently. That's a 361.53% change in annual revenue.
Voyager Therapeutics annual revenue
Voyager Therapeutics annual revenue over time
| Fiscal year / year | Voyager Therapeutics revenue |
|---|---|
| 2015 | $17.3M |
| 2016 | $14.2M |
| 2017 | $10.1M |
| 2018 | $7.6M |
| 2019 | $104.4M |
| 2020 | $171.1M |
| 2021 | $37.4M |
| 2022 | $40.9M |
| 2023 | $250.0M |
| 2024 | $80.0M |
How accurately did Voyager Therapeutics' revenue projections match actual performance?
Voyager Therapeutics annual growth
Voyager Therapeutics saw the greatest revenue growth in 2019, when revenue increased by 1,270.14%.
Voyager Therapeutics had the lowest revenue growth in 2021, when revenue changed by -78.14%.
Voyager Therapeutics annual growth rate over time
| Year | Voyager Therapeutics growth |
|---|---|
| 2016 | -18%↓ |
| 2017 | -29%↓ |
| 2018 | -25%↓ |
| 2019 | 1270%↑ |
| 2020 | 64%↑ |
| 2021 | -78%↓ |
| 2022 | 9%↑ |
| 2023 | 511%↑ |
| 2024 | -68%↓ |
Voyager Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Voyager Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2015 | - | - | $4.9M | $4.9M |
| 2016 | $4.8M | $3.7M | $3.3M | $2.4M |
| 2017 | $1.5M | $1.2M | $1.1M | $6.3M |
| 2018 | $942,000 | $2.6M | $2.1M | $2.0M |
| 2019 | $5.2M | $46.1M | $20.4M | $32.7M |
| 2020 | $18.1M | $28.7M | $117.8M | $6.5M |
| 2021 | $6.5M | $1.4M | $1.5M | $28.1M |
| 2022 | $658,000 | $712,000 | $41.1M | ($1.5M) |
| 2023 | $150.5M | $4.9M | $4.6M | $90.1M |
| 2024 | $19.5M | $29.6M | $24.6M | $6.3M |
Voyager Therapeutics jobs nearby
Do you work at Voyager Therapeutics?
Is Voyager Therapeutics transparent about its revenue structure?
Voyager Therapeutics financial information
| CEO | Steven Paul |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 123 |
| Date Founded | 2013 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 2 |
| Revenue | $80.0M |
| Net Income | -$46,408,000 |
| Tax Rate | -0.0% |
| Total Assets | $159,356,000 |
| Ticker | VYGR |
Voyager Therapeutics jobs you might like
Voyager Therapeutics financing
Voyager Therapeutics received early financing of $45.0M on 2014-02-12.
| Series | Round size | Date |
|---|---|---|
| Series A | $45M | 02/2014 |
| Corporate Round | $30M | 02/2015 |
| Series B | $60M | 04/2015 |
Voyager Therapeutics investors
| Investors | Security type |
|---|---|
| Third Rock Ventures | Series A |
| GENZYME CORP | Corporate Round |
| Brookside Capital Inc | Series B |
| Partner Fund Management | Series B |
| Wellington Management | Series B |
| Deerfield | Series B |
| FMR Co. | Series B |
| Casdin Capital | Series B |
Voyager Therapeutics competitors
Voyager Therapeutics's top competitor, Acorda Therapeutics, earned an annual revenue of $117.6M.
Voyager Therapeutics's smallest competitor is Brainstorm Cell Therapeutics with revenue of $82.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Dimension Therapeutics | - | $11.5M | 59 | - |
| Rocket Pharmaceuticals | - | $11.8M | 50 | - |
| AVROBIO | - | $1.2M | 49 | - |
| Brainstorm Cell Therapeutics | - | $82,000 | 40 | - |
| ProMIS Neurosciences | - | $284.9K | 15 | - |
| Prevail Therapeutics | - | $74.3M | 66 | - |
| Affinia Therapeutics | - | $2.0M | 75 | - |
| Acorda Therapeutics | - | $117.6M | 344 | - |
| Abbott Molecular | - | $74.5M | 125 | - |
| Caliper Life Sciences | - | $109.8M | 200 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Voyager Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Voyager Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Voyager Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Voyager Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Voyager Therapeutics. The data presented on this page does not represent the view of Voyager Therapeutics and its employees or that of Zippia.
Voyager Therapeutics may also be known as or be related to VOYAGER THERAPEUTICS INC., Voyager Therapeutics, Voyager Therapeutics Inc and Voyager Therapeutics, Inc.